NEXGEL Q3: record revenue $1.2M (+115% YoY), net loss -$550K, gross margin 28.2%

NEXGEL, INC.

2023-Q3 EPS reported -$0.36 revenue$3,007,000

Revenue $1.2M, up 115% YoY from $568K; growth in contract manufacturing and branded products.
Gross profit margin 28.2% vs 26.1% YoY, sequentially improved from 15% in Q2 2023.
Net loss -$550K ($0.10/sh) vs -$1.2M ($0.22/sh) in Q3 2022; improved from -$642K in Q2 2023.
Operating expenses fell to $956K from $1.185M YoY; cash $3.3M as of Sep 30, 2023.
New supply agreement with AbbVie (ABBV) for gel pads; Enigma Health retail partnership announced.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NEXGEL, INC. reported third quarter ended September 30, 2023 results: revenue $1.2 million, EPS $0.10 per basic and diluted share.

Period: third quarter ended September 30, 2023
Revenue: $1.2 million
EPS: $0.10 per basic and diluted share
Result: reported results

Exact text from the filing

shall be expressly set forth by specific reference in such a filing. --- EX-99.1 () --- EX-99.1 2 ex99-1.htm Exhibit 99.1 NEXGEL Reports Record Third Quarter 2023 Revenue of $1.2 Million, an Increase of 115% Year-Over-Year Gross profit margin improved sequentially to 28.2% in Q3 as compared to 15.0% in Q2 LANGHORNE, Pa. – November 13, 2023 – NEXGEL, Inc.

View on SEC.gov

Browse all earnings releases →

NEXGEL, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-040614

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.